Dr. Saima Chohan, MD
Rheumatology (Rheumatology Physician)
4550 E Bell Rd, Suite 170
Phoenix, AZ 85032
Who else practices at this address →
Maricopa County includes primary care (13% of residents) and dental (0% of residents) and mental health (4% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Cincinnati College of Medicine (1998)
- Years since graduation
- 28
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 903
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1998Medical school: University of Cincinnati College of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Rheumatology Physician primary
AZ license 47438
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Arizona Arthritis and Rheumatology Associates P C (65 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 903
- Services billed
- 322,993
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, tocilizumab, 1 mg | 79,503 | 27 |
| Injection, golimumab, 1 mg, for intravenous use | 56,652 | 87 |
| Injection, romosozumab-aqqg, 1 mg | 52,290 | 58 |
| Injection, certolizumab pegol, 1 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 40,400 | 14 |
| Injection, denosumab, 1 mg | 36,780 | 389 |
| Hyaluronan or derivative, gelsyn-3, for intra-articular injection, 0.1 mg | 17,309 | 20 |
| Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 15,550 | 33 |
| Injection, infliximab, excludes biosimilar, 10 mg | 2,600 | 22 |
| Injection, rituximab, 10 mg | 2,580 | 11 |
| Injection, infliximab-abda, biosimilar, (renflexis), 10 mg | 1,870 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Methotrexate (methotrexate sodium) Other prescribers in Phoenix, AZ | 509 |
| Hydroxychloroquine Sulfate Other prescribers in Phoenix, AZ | 307 |
| Prednisone Other prescribers in Phoenix, AZ | 221 |
| Leflunomide Other prescribers in Phoenix, AZ | 218 |
| Folic Acid Other prescribers in Phoenix, AZ | 134 |
| Allopurinol Other prescribers in Phoenix, AZ | 120 |
| Enbrel Sureclick (etanercept) Other prescribers in Phoenix, AZ | 110 |
| Alendronate Sodium Other prescribers in Phoenix, AZ | 77 |
| Humira(Cf) Pen (adalimumab) Other prescribers in Phoenix, AZ | 56 |
| Gabapentin Other prescribers in Phoenix, AZ | 44 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 22 companies reported 126 payments worth $2,515 in total to this clinician.
| AbbVie Inc. | $467 |
|---|---|
| Amgen Inc. | $435 |
| UCB, Inc. | $431 |
| Janssen Biotech, Inc. | $160 |
| Radius Health, Inc. | $144 |
| E.r. Squibb & Sons, L.l.c. | $114 |
| Pfizer Inc. | $113 |
| Fresenius Kabi USA, LLC | $106 |
| Food and Beverage | $2,416 |
|---|---|
| Education | $99.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Oct 21, 2025 | Education TREMFYA · Immunology · in-kind | $99.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 5 companies. The companies reported $931,082 in research payments for these studies, mostly to the institutions running them.
- A study to Evaluate the Efficacy and Safety of Dosing KRYSTEXXA (pegloticase) + MTX in Participants
Amgen Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgren's Syndrome With Moderate-to-severe Systemic Disease Activity
Amgen Inc. - Efficacy and Safety of Tildrakizumab Compared to Placebo in Subjects With Active Psoriatic Arthritis I (INSPIRE 1)
Sun Pharmaceutical Industries Inc. - A Multicenter, Open-Label, Long-term, Extension Study to Evaluate the Safety and Tolerability of Dazodalibep in Participants With Sjgren's Syndrome (SS)
Amgen Inc. - A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Amgen Inc. - A Multicenter Randomized Double-blind Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of Subcutaneous Anifrolumab in Adult Patients with Systemic Lupus Erythematosus
AstraZeneca UK Limited - A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult P…
Argenx US, Inc. - A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis
Amgen Inc. - A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity
Amgen Inc. - A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic…
Takeda Pharmaceuticals U.S.A., Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.